Abstract:Objective: To investigate the effect of conbercept or laser in the treatment of branch retinal vein occlusion (BRVO) with macular edema, and to analyze the relationship between visual acuity and the central macular thickness (CMT) and the outer nuclear layer thickness (ONLT). Methods: 89 cases (89 eyes) of BRVO patients with macular edema treated in our hospital from March 2016 to June 2019 were randomly divided into the observation group (45 cases and 45 eyes) and the control group (44 cases and 44 eyes). The observation group was treated with conbercept and fundus laser, and the control group was treated with leizhumab and fundus laser. BCVA, CMT, ONLT and macular leakage were observed. the relationship between BCVA, CMT andONLT were analyzed. Results: There was significant difference in BCVA at different time and time interaction between groups (P<0.05), but no significant difference between groups (P>0.05). CMT and ONLT had significant difference in different time (P<0.05), but no significant difference in the interaction between groups and time (P>0.05). The CMT and ONLT of the two groups decreased with the time after treatment, and BCVA increased. The CMT and ONLT of the two groups were lower than before treatment at different time points after treatment, and BCVA was higher than before treatment (P>0.05). The BCVA of the observation group was higher than that of the control group at 1, 2 and 3 months after treatment, the CMT of the observation group was lower than that of the control group at 3 months after treatment, and the ONLT of the observation group was lower than that of the control group at 2 and 3 months after treatment (P<0.05). Conclusion: The effect of conbercept combined with fundus laser in BRVO patients with macular edema is better than that of leizhumab combined with fundus laser. It has high security.
宋清雪, 马鹤. 康柏西普或雷珠单抗联合激光治疗BRVO合并黄斑水肿的效果比较[J]. 河北医学, 2020, 26(5): 713-717.
SONG Qingxue, MA He. Comparison of the Effect of Conbercept or Rapunzumab Combined with Laser in the Treatment of BRVO with Macular Edema. HeBei Med, 2020, 26(5): 713-717.